share_log

Advanced Health Intelligence Signs Letter of Intent to Develop and Deploy a Digital Underwriting Solution For the Insurance Industry

Advanced Health Intelligence Signs Letter of Intent to Develop and Deploy a Digital Underwriting Solution For the Insurance Industry

Advanced Health Intelligence签署意向书,为保险业开发和部署数字承保解决方案
newsfile ·  2023/09/20 06:58

Highlights

亮点

  • AHI signs a letter of Intent with Unisure.
  • AHI与联合国教科文组织签署了意向书。
  • SCOR (SCR.FP) and Unisure to collaborate with AHI.
  • SCOR(SCR.FP)和安康与AHI合作。
  • SCOR is one of the world's largest Reinsurers.
  • SCOR是世界上最大的再保险公司之一。
  • AHI will deploy a digital underwriting capability using AHI's Biometric Health Assessment.
  • AHI将使用AHI的生物识别健康评估部署数字承保能力。
  • AHI is to Digitise phenotypical Biometric data for insurance underwriting purposes.
  • AHI将把表型生物识别数据数字化,用于保险承保目的。

South Perth, Australia--(Newsfile Corp. - September 20, 2023) - Advanced Health Intelligence Ltd (ASX: AHI) (NASDAQ: AHI) ("AHI" or "the Company") is pleased to inform shareholders that the Company has entered a Letter of Intent (LOI) with UK-based Unisure Group to design, develop and deploy the AHI Biometric Health Assessment (BHA).

澳大利亚南珀斯-(Newsfile Corp.-2023年9月20日)-先进健康智能有限公司 (ASX:ahi)(纳斯达克:ahi)(“ahi”或“公司”)我们很高兴地通知股东,公司已经与总部位于英国的安康集团签署了一份意向书,以设计、开发和部署AHI生物识别健康评估(BHA)。

The LOI is a result of exploratory discussions between AHI, SCOR and Unisure over several months, resulting in SCOR partnering with Unisure to develop and deploy the digital application with AHI.

意向书是AHI、SCOR和联合国休闲中心几个月来探索性讨论的结果,导致SCOR与联合国休闲中心合作开发和部署与AHI的数字应用程序。

Unisure and AHI have executed a Letter of Intent to develop and deploy a world-first digital underwriting solution utilising AHI's revolutionary smartphone-based biometric health risk assessment. The intent of the relationship is to create a series of innovative insurance offerings by leveraging AHI's technology with SCOR's wealth of Reinsurance knowledge to service the global retail insurance market. Partnering with Unisure and SCOR presents a unique opportunity that will utilise the proprietary AHI digital blood biomarkers and phenotypical data combined with insurers' rich actuarial and underwriting data to develop and design new digital underwriting solutions.

安康和AHI签署了一份意向书,利用AHI革命性的基于智能手机的生物识别健康风险评估,开发和部署全球首个数字承保解决方案。双方合作的目的是通过利用AHI的技术和SCOR丰富的再保险知识来创建一系列创新的保险产品,为全球零售保险市场服务。与安康和SCOR的合作提供了一个独特的机会,将利用专有的AHI数字血液生物标记物和表型数据,结合保险公司丰富的精算和承保数据来开发和设计新的数字承保解决方案。

The collaboration will result in SCOR and Unisure deploying AHI's technology to digitally assess the health risk across a minimum of 5,000 individuals as part of a health screening for insurance requirements.

这项合作将导致SCOR和联合国休闲中心部署AHI的技术,以数字方式评估至少5000人的健康风险,作为保险要求健康筛查的一部分。

The intention is that this will be the first in a series of AHI's insurance market product developments to digitise risk underwriting, which can be used to augment traditional blood pathology underwriting over time. The breadth of AHI's 61 health outputs, resulting in 41 biometric captures across five major health and disease risk categories - cardio-respiratory, body composition, estimated blood biomarkers, metabolic health and mental health offers comprehensive insights for morbidity and mortality risk highly relevant to health and life policy pricing. AHI is in a distinctive position to work alongside insurers to cost-effectively unlock the large, unpenetrated, and un-serviced middle market where traditional medical underwriting is now deemed too slow and expensive.

其意图是,这将是AHI将风险承保数字化的一系列保险市场产品开发中的第一个,随着时间的推移,这种产品可用于增强传统的血液病理承保。AHI的61项健康产出的广度,产生了五个主要健康和疾病风险类别-心肺、身体成分、估计血液生物标记物、代谢健康和精神健康-的41个生物识别捕获,提供了与健康和人寿保险定价高度相关的发病率和死亡率风险的全面洞察。AHI处于一个独特的地位,可以与保险公司合作,以经济高效的方式打开庞大的、未被渗透和未得到服务的中端市场,在这个市场上,传统的医疗承保现在被认为过于缓慢和昂贵。

Dylan Garnett, Chief Innovation Officer at AHI, said:

AHI首席创新官迪伦·加内特表示:

"With more than two decades of experience in the insurance industry, I've witnessed its evolution, particularly the growing need for digital transformation in insurance underwriting. This transition is to deliver a more cost-effective and precise approach to assessing the appropriate coverage for individuals. Unisure is an ideal collaborator for the initial implementation of the BHA underwriting solution. We will launch the program involving a minimum of 5,000 participants, which will be crucial learnings in providing us with feedback and helping us shape the perfect product offering for the market. We value these participants immensely, as they represent a manageable segment for our solution's iterative development and refining.

凭借在保险业二十多年的经验,我亲眼目睹了保险行业的发展,特别是保险承保领域对数字化转型的日益增长的需求。这种转变是为了提供一种更具成本效益和精确度的方法来评估个人的适当保险范围。对于BHA承保解决方案的初始实施来说,Unseing是一个理想的合作伙伴。我们将启动该计划,至少有5000名参与者参与,这将是为我们提供反馈和帮助我们为市场塑造完美产品产品的关键学习。我们非常重视这些参与者,因为他们代表着我们解决方案迭代开发和完善的可管理部分。

AHI and SCOR, as partners, align perfectly with our philosophy and demonstrate a robust commitment to their clients. SCOR is a particularly suitable partner for AHI due to their client-centric approach. They customise their reinsurance solutions to meet their client's individual needs and risk profiles. SCOR's experienced underwriters and risk analysts work in close collaboration with clients to create comprehensive yet cost-effective risk strategies. This shared philosophy will be instrumental in our success as we move forward."

AHI和SCOR作为合作伙伴,与我们的理念完美地结合在一起,并展示了对客户的坚定承诺。SCOR是AHI特别合适的合作伙伴,因为他们以客户为中心。他们定制他们的再保险解决方案,以满足客户的个人需求和风险状况。SCOR的经验丰富的承销商和风险分析师与客户密切合作,制定全面而具成本效益的风险策略。在我们前进的过程中,这种共同的理念将有助于我们取得成功。“

Vlado Bosanac, AHI Founder and Head of Strategy, said:

AHI创始人兼战略主管弗拉多·博萨纳克表示:

"This Letter of Intent (LOI) brings a significant partnership to AHI with SCOR and Unisure Group. The collaboration signifies a major milestone in our journey to demonstrate to the insurance industry the powerful data AHI delivers to assist the industry in better understanding their policyholders, their health and the appropriate coverage they need. By leveraging AHI's innovative technology with the industry knowledge brought by SCOR and Unisure's expertise, we are poised to create a world-first on-device biometric digital underwriting solution. This partnership enhances our industry understanding of digital insurance tools and positions AHI at the forefront of the digital insurance revolution, unlocking cost-effective solutions for the unpenetrated middle market."

这份意向书(LOI)为AHI与SCOR和康乐集团带来了重要的合作伙伴关系。这项合作标志着我们向保险业展示AHI提供的强大数据以帮助保险业更好地了解其投保人、他们的健康和他们所需的适当保险的旅程中的一个重要里程碑。通过利用AHI的创新技术和SCOR带来的行业知识,以及安康的专业知识,我们准备创建世界首个设备上生物识别数字承保解决方案。这一合作关系增强了我们行业对数字保险工具的理解,并将AHI定位在数字保险革命的前沿,为未渗透的中间市场解锁了高性价比的解决方案。

AHI anticipates that revenue generation through this agreement will commence upon the initial deployment of the solution. The Company will continuously update our shareholders regarding the progress leading up to and including the commercial launch.

AHI预计,通过这项协议产生的收入将从解决方案的初始部署开始。公司将不断向我们的股东通报商业推出前的进展情况,包括商业推出的进展情况。

This announcement has been approved by the Chairman and CEO of Advanced Health Intelligence Ltd.

这一公告已得到Advanced Health Intelligence Ltd.董事长兼首席执行官的批准。

For more information, contact:

如需更多信息,请联系:

Dylan Garnett
Chief Innovation Officer
Advanced Health Intelligence Ltd
E: admin@ahi.tech

迪伦·加内特
首席创新官
先进健康智能有限公司
电子邮箱:admin@ahi.tech

Vlado Bosanac
Founder/Head of Strategy
Advanced Health Intelligence Ltd
E: admin@ahi.tech

弗拉多·博萨纳克
创始人/战略主管
先进健康智能有限公司
电子邮箱:admin@ahi.tech

About Unisure Group

关于康乐集团

Unisure is an international health and life insurance solutions provider with offices on four continents. They provide SMEs with Group Life and Disability and Group Business Protection insurance solutions, as well as personalised solutions for employers who have employees that travel across borders. Unisure also provides individuals with a range of international life insurance solutions. They have their own medical clinics in Zambia and offer International Private Medical Insurance solutions globally. They distribute their solutions through intermediaries, insurance brokers and financial advisers.

安康是一家国际健康和人寿保险解决方案提供商,在四大洲设有办事处。他们为中小企业提供团体人寿和残疾保险解决方案和团体商业保护保险解决方案,以及为有员工跨境旅行的雇主提供个性化解决方案。安康还为个人提供一系列国际人寿保险解决方案。他们在赞比亚拥有自己的医疗诊所,并在全球提供国际私人医疗保险解决方案。他们通过中间人、保险经纪人和金融顾问分发他们的解决方案。

Unisure's vision is to be a loved and trusted global insurance provider, protecting one million families every year through dynamic, equitable, and fully portable insurance solutions.

安康的愿景是成为一家受人喜爱和信赖的全球保险提供商,每年通过动态、公平和完全便携的保险解决方案保护100万个家庭。

For more information, visit and .

有关更多信息,请访问和。

About SCOR

关于SCOR

SCOR, a leading global reinsurer, offers its clients a diversified and innovative range of reinsurance and insurance solutions and services to control and manage risk. Applying "The Art & Science of Risk", SCOR uses its industry-recognized expertise and cutting-edge financial solutions to serve its clients and contribute to the welfare and resilience of society. SCOR offers its clients a Tier 1 reinsurer rating from Standard & Poor's, AM Best, Moody's and Fitch. The Group generated premiums of EUR 19.7 billion in 2022 and serves clients in more than 160 countries from its 35 offices worldwide. For more information, visit: .

SCOR是一家全球领先的再保险公司,为其客户提供多元化和创新的再保险和保险解决方案及服务,以控制和管理风险。应用“风险的艺术与科学”,SCOR利用其行业公认的专业知识和尖端的金融解决方案为客户服务,并为社会的福利和韧性做出贡献。SCOR为其客户提供来自标准普尔、AM Best、穆迪和惠誉的一级再保险公司评级。该集团在2022年创造了197亿欧元的保费收入,并通过其全球35个办事处为160多个国家和地区的客户提供服务。有关更多信息,请访问:。

About Advanced Health Intelligence Ltd

关于先进健康智能有限公司

Advanced Health Intelligence Ltd ('AHI') delivers scalable health assessment, risk stratification and digital triage capabilities to healthcare providers, insurers, employers, and government agencies worldwide via our proprietary technology and processes.

先进健康智能有限公司(“AHI”)通过我们的专有技术和流程,为世界各地的医疗保健提供者、保险公司、雇主和政府机构提供可扩展的健康评估、风险分层和数字分诊功能。

Since 2014, AHI has been delivering Health-tech innovation via a smartphone, starting with the world's first on-device body dimensioning capability. AHI has developed a patented technology, showcasing the next frontier in digitising healthcare with a suite of componentised solutions, culminating in:

自2014年以来,AHI一直通过智能手机提供健康科技创新,首先是世界上第一个设备上的人体尺寸测量功能。AHI开发了一项专利技术,通过一套组件化解决方案展示了数字化医疗的下一个前沿,最终实现了:

  • Body dimension and composition assessment to identify the comorbidities of obesity, such as diabetes risk estimates.
  • Blood biomarker prediction, including HbA1C, HDL, LDL, and 10-year mortality risk.
  • Transdermal Optical Imaging to return vital signs and cardiovascular disease risk estimates.
  • On-device dermatological skin identification across 588 skin conditions across 133 categories (Inc. Melanoma); and
  • Assisting partners in delivering personalised therapeutic and non-therapeutic health coaching to improve daily habits and build health literacy.
  • 身体尺寸和成分评估,以确定肥胖的共病,如糖尿病风险估计。
  • 血液生物标志物预测,包括HbA1C、高密度脂蛋白、低密度脂蛋白和10年死亡风险。
  • 经皮光学成像返回生命体征和心血管疾病风险评估。
  • 在133个类别的588种皮肤疾病(包括黑色素瘤)中进行设备上的皮肤科皮肤识别;以及
  • 协助合作伙伴提供个性化的治疗性和非治疗性健康指导,以改善日常习惯和培养健康素养。

Our world-class team of subject matter experts in machine learning, AI, computer vision, and medically trained data scientists ensure that AHI's technology is at the forefront of innovation and the needs of our consumers.

我们由机器学习、人工智能、计算机视觉和受过医学培训的数据科学家组成的世界级主题专家团队确保了AHI的技术处于创新的前沿,并满足了我们消费者的需求。

With a focus on impact at scale, AHI is proud to showcase this milestone in digital healthcare transformation, delivering a biometrically derived triage solution accessible on and via a smartphone. With these advanced technologies, AHI helps its partners identify risks across their consumers and triage them into right-care pathways for proactive health management at a population scale.

凭借对规模影响的关注,AHI自豪地展示了数字医疗转型的这一里程碑,提供了可在智能手机上和通过智能手机访问的生物识别派生分诊解决方案。有了这些先进的技术,AHI帮助其合作伙伴识别其消费者的风险,并将他们分流到正确的保健路径,以便在人口规模上进行主动健康管理。

For more information, please visit:

如需更多信息,请访问:

Cautionary Note Regarding Forward-Looking Statements:

有关前瞻性陈述的注意事项:

This news release contains information or statements that constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements, or developments to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by words such as "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "potential" and similar expressions, or that events or conditions "will," "would," "may," "could" or "should" occur.

本新闻稿包含构成“前瞻性陈述”的信息或陈述。此类前瞻性表述涉及已知和未知的风险、不确定性和其他因素,可能导致实际结果、业绩或成就或发展与此类前瞻性表述明示或暗示的预期结果、业绩或成就大不相同。前瞻性陈述是指不是历史事实的陈述,通常但并非总是通过“预期”、“计划”、“预期”、“相信”、“打算”、“估计”、“项目”、“潜在”和类似的表述,或事件或条件“将”、“将”、“可能”、“可能”或“应该”发生等词语来识别。

Forward-looking information may include, without limitation, statements regarding the operations, business, financial condition, expected financial results, performance, prospects, opportunities, priorities, targets, goals, ongoing objectives, milestones, strategies, and outlook of Advance Health Intelligence, and includes statements about, among other things, future developments and the future operations, strengths, and strategies of Advance Health Intelligence. Forward-looking information is provided for the purpose of presenting information about management's current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. These statements should not be read as guarantees of future performance or results.

前瞻性信息可能包括但不限于关于Advance Health Intelligence的运营、业务、财务状况、预期财务结果、业绩、前景、机会、优先事项、目标、目标、持续目标、里程碑、战略和展望的陈述,还包括关于Advance Health Intelligence的未来发展和未来运营、优势和战略的陈述。提供前瞻性信息的目的是提供有关管理层目前对未来的期望和计划的信息,请读者注意,此类陈述可能不适用于其他目的。这些声明不应被解读为对未来业绩或结果的保证。

The forward-looking statements made, or perceived to be made, in this news release are based on management's assumptions and analysis and other factors that may be drawn upon by management to form conclusions and make forecasts or projections, including management's experience and assessments of historical trends, current conditions and expected future developments. Although management believes that these assumptions, analysis, and assessments are reasonable at the time the statements contained in this news release are made, actual results may differ materially from those projected in any forward-looking statements. Examples of risks and factors that could cause actual results to materially differ from forward-looking statements may include: the timing and unpredictability of regulatory actions; regulatory, legislative, legal or other developments with respect to its operations or business; limited marketing and sales capabilities; early stage of the industry and product development; limited products; reliance on third parties; unfavorable publicity or consumer perception; general economic conditions and financial markets; the impact of increasing competition; the loss of key management personnel; capital requirements and liquidity; access to capital; the timing and amount of capital expenditures; the impact of COVID-19; shifts in the demand for Advanced Health Intelligence's products and the size of the market; patent law reform; patent litigation and intellectual property; conflicts of interest; and general market and economic conditions.

本新闻稿中作出或被视为作出的前瞻性陈述是基于管理层的假设和分析以及管理层可能利用的其他因素,包括管理层对历史趋势、当前状况和预期未来发展的经验和评估,以得出结论并做出预测或预测。尽管管理层认为这些假设、分析和评估在作出本新闻稿中包含的陈述时是合理的,但实际结果可能与任何前瞻性陈述中所预测的大不相同。可能导致实际结果与前瞻性声明大不相同的风险和因素包括:监管行动的时机和不可预测性;与其运营或业务有关的监管、立法、法律或其他事态发展;营销和销售能力有限;行业和产品开发的早期阶段;有限的产品;对第三方的依赖;不利的宣传或消费者看法;总体经济状况和金融市场;竞争加剧的影响;关键管理人员的流失;资本要求和流动性;获得资本的机会;资本支出的时机和数额;新冠肺炎的影响;对先进健康智能产品的需求和市场规模的变化;专利法改革;专利诉讼和知识产权;利益冲突;以及总体市场和经济状况。

The forward-looking information contained in this news release represents the expectations of Advance Health Intelligence as of the date of this news release and, accordingly, is subject to change after such date. Readers should not place undue importance on forward-looking information and should not rely upon this information as of any other date. Advance Health Intelligence undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.

本新闻稿中包含的前瞻性信息代表了截至本新闻稿发布之日对Advance Health Intelligence的期望,因此,在该日期之后可能会发生变化。读者不应过分重视前瞻性信息,也不应依赖截至任何其他日期的这些信息。Advance Health Intelligence没有义务在管理层的信念、估计或意见或其他因素发生变化时更新这些前瞻性陈述。

To view the source version of this press release, please visit

要查看本新闻稿的源版本,请访问

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发